Don’t miss this activity, featuring an in-depth look at the latest clinical evidence for JAK inhibitors and emerging novel therapies in the treatment of myelofibrosis (MF), with a focus on care in federal, public, and government healthcare settings. Experts will share practical strategies for integrating prognostic assessment tools to guide individualized JAK inhibitor selection, optimizing adverse event management, and identifying disease progression or relapse.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/jak-inhibitors-beyond-assessing-novel-approaches-myelofibrosis-treatment
- Start Date: 2024-11-27 06:00:00
- End Date: 2024-11-27 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Daiichi Sankyo, Inc. - Amount: 6250.0 - Is Kind Support: False Source: Janssen (Any division) - Amount: 9375.0 - Is Kind Support: False Source: Sanofi S.A. - Amount: 7437.5 - Is Kind Support: False Source: Sobi - Amount: 6250.0 - Is Kind Support: False Source: Taiho Pharmaceutical - Amount: 12437.5 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest